Core Viewpoint - The company has approved a licensing and commercialization agreement for BAT2206, receiving a milestone payment of $2.5 million from Jireh Pharmaceuticals, which enhances its cash reserves and supports future pipeline development and international strategy [1] Group 1: Financial Impact - The company received a one-time milestone payment of $2.5 million, which strengthens its cash reserves [1] - The payment is expected to assist in the advancement of the company's pipeline research and international strategy [1] Group 2: Product Development - BAT2206 injection has been approved for market by the U.S. FDA and the European Medicines Agency, with the U.S. brand name STARJEMZA® and the European brand name Usymro® [1] - The company has submitted a marketing application to the National Medical Products Administration, which is currently under review [1]

Group 1 - The company reported a revenue of 1.1 billion yuan (+48%) for the first half of 2025, with a net loss attributable to shareholders of 450 million yuan, meeting expectations [1] - Core products are experiencing continuous growth, with over 1,000 hospitals approved for both autoimmune and oncology treatments. The commercialization team for autoimmune diseases has approximately 900 members, while the oncology team has over 500 members [1] - The company successfully licensed Tai'tasip for the treatment of myasthenia gravis to Vor Bio, receiving an upfront payment of 45 million USD and potential milestone payments totaling up to 4.105 billion USD [2] Group 2 - The company licensed RC28 to Santen China, receiving an upfront payment of 250 million yuan and potential milestone payments totaling up to 525 million yuan [3] - The company expects revenues of 2.21 billion, 2.95 billion, and 4.26 billion yuan for the years 2025, 2026, and 2027, respectively, driven by the continued growth of Tai'tasip and Vidi'simab [3]